Special Issue "SARS-CoV-2: Vaccines in the Pandemic Era"
Deadline for manuscript submissions: 31 December 2023 | Viewed by 1477
Interests: viral innate immune response; vaccine; single-cell sequence
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19), which emerged in December 2019 in Wuhan, China. Symptoms of SARS-CoV-2 infection are primarily respiratory, although an increasing number of other syndromes such as cognitive deficits have been reported. As of 17 November 2022, the COVID-19 pandemic has resulted in more than 636 million infections with over 6.6 million deaths (https://coronavirus.jhu.edu/). Since the pandemic, multiple SARS-CoV-2 vaccine platforms have been successfully developed for COVID-19, including messenger RNA (mRNA), inactivated virus, adenovirus vectors (Ad26.COV2.S and ChAdOx1), and spike (S) protein subunit vaccine. These vaccines demonstrate high efficacy against SARS-CoV-2 and dramatical reduction in viral transmission, hospitalization, and deaths following two intramuscular injections. However, an increasing number of new SARS-CoV-2 variants of concern (VOCs) have emerged, including the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and recently dominant circulating Omicron variant. These emerging SARS-CoV-2 VOCs have significantly impaired the effectiveness of current SARS-CoV-2 vaccines.
To achieve a more extensive understanding of recent scientific knowledge in SARS-CoV-2 vaccines, this Special issue focuses on SARS-CoV-2 vaccine development. We invite you contribute original research and reviews papers on SARS-CoV-2. Topics of interest range from SARS-CoV-2 vaccine development to preclinical research and clinical evaluation.
Dr. Weihong Gu
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- vaccine design
- vaccine development
- immune responses